Plasminogen Activator Inhibitor-1 in Aging

 

 Buy Article Permissions and Reprints

Abstract

Plasminogen activator inhibitor-1 (PAI-1), a principal inhibitor of fibrinolysis, is induced in thrombotic, fibrotic, and cardiovascular diseases, which in turn primarily afflict the older population. This induction of PAI-1 may play an important role in the pathology of these diseases as PAI-1 can regulate the dissolution of fibrin and also inhibit the degradation of the extracellular matrix by reducing plasmin generation. PAI-1 expression is elevated in aged individuals and is significantly upregulated in a variety of pathologies associated with the process of aging, including myocardial and cerebral infarction, vascular (athero) sclerosis, cardiac and lung fibrosis, metabolic syndromes (e.g., hypertension, hyperlipidemia, and insulin resistance), cancer, and inflammatory/stress responses. Thus, PAI-1 may play a critical role in the development of aging-associated pathological changes. In addition, PAI-1 is recognized as a marker of senescence and a key member of a group of proteins collectively known as the senescence-messaging secretome. In this review, we highlight the role of PAI-1 in the pathophysiology of aging and aging-associated disorders.

• References

• 1 Tracy RP, Bovill EG. Thrombosis and cardiovascular risk in the elderly. Arch Pathol Lab Med 1992; 116 (12) 1307-1312
  PubMedGoogle Scholar
• 2 Wilkerson WR, Sane DC. Aging and thrombosis. Semin Thromb Hemost 2002; 28 (6) 555-568
  Article in Thieme ConnectPubMedGoogle Scholar
• 3 Kiechl S, Willeit J ; Bruneck Study Group. The natural course of atherosclerosis. Part II: vascular remodeling. Arterioscler Thromb Vasc Biol 1999; 19 (6) 1491-1498
  CrossrefPubMedGoogle Scholar
• 4 Koster T, Rosendaal FR, Reitsma PH, van der Velden PA, Briët E, Vandenbroucke JP. Factor VII and fibrinogen levels as risk factors for venous thrombosis. A case-control study of plasma levels and DNA polymorphisms—the Leiden Thrombophilia Study (LETS). Thromb Haemost 1994; 71 (6) 719-722
  PubMedGoogle Scholar
• 5 Abbate R, Prisco D, Rostagno C, Boddi M, Gensini GF. Age-related changes in the hemostatic system. Int J Clin Lab Res 1993; 23 (1) 1-3
  CrossrefPubMedGoogle Scholar
• 6 Hashimoto Y, Kobayashi A, Yamazaki N, Sugawara Y, Takada Y, Takada A. Relationship between age and plasma t-PA, PA-inhibitor, and PA activity. Thromb Res 1987; 46 (5) 625-633
  CrossrefPubMedGoogle Scholar
• 7 Loskutoff DJ, Sawdey M, Mimuro J. Type 1 plasminogen activator inhibitor. In: Coller B, , ed. Progress in Hemostasis and Thrombosis. Philadelphia, PA: WB Saunders Company; 1988: 87-115
  Google Scholar
• 8 Yamamoto K, Saito H. A pathological role of increased expression of plasminogen activator inhibitor-1 in human or animal disorders. Int J Hematol 1998; 68 (4) 371-385
  CrossrefPubMedGoogle Scholar
• 9 Yamamoto K, Takeshita K, Kojima T, Takamatsu J, Saito H. Aging and plasminogen activator inhibitor-1 (PAI-1) regulation: implication in the pathogenesis of thrombotic disorders in the elderly. Cardiovasc Res 2005; 66: 276-285
  CrossrefPubMedGoogle Scholar
• 10 Stefansson S, Lawrence DA. The serpin PAI-1 inhibits cell migration by blocking integrin alpha V beta 3 binding to vitronectin. Nature 1996; 383 (6599) 441-443
  CrossrefPubMedGoogle Scholar
• 11 Heymans S, Luttun A, Nuyens D , et al. Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure. Nat Med 1999; 5 (10) 1135-1142
  CrossrefPubMedGoogle Scholar
• 12 Eren M, Gleaves LA, Atkinson JB, King LE, Declerck PJ, Vaughan DE. Reactive site-dependent phenotypic alterations in plasminogen activator inhibitor-1 transgenic mice. J Thromb Haemost 2007; 5 (7) 1500-1508
  CrossrefPubMedGoogle Scholar
• 13 Loskutoff DJ. Regulation of PAI-1 gene expression. Fibrinolysis 1991; 5: 197-206
  CrossrefPubMedGoogle Scholar
• 14 Sawdey MS, Loskutoff DJ. Regulation of murine type 1 plasminogen activator inhibitor gene expression in vivo. Tissue specificity and induction by lipopolysaccharide, tumor necrosis factor-α, and transforming growth factor-β. J Clin Invest 1991; 88 (4) 1346-1353
  CrossrefPubMedGoogle Scholar
• 15 Yamamoto K, Loskutoff DJ. Fibrin deposition in tissues from endotoxin-treated mice correlates with decreases in the expression of urokinase-type but not tissue-type plasminogen activator. J Clin Invest 1996; 97 (11) 2440-2451
  CrossrefPubMedGoogle Scholar
• 16 Samad F, Yamamoto K, Loskutoff DJ. Distribution and regulation of plasminogen activator inhibitor-1 in murine adipose tissue in vivo. Induction by tumor necrosis factor- α and lipopolysaccharide. J Clin Invest 1996; 97 (1) 37-46
  CrossrefPubMedGoogle Scholar
• 17 Yamamoto K, Takeshita K, Shimokawa T , et al. Plasminogen activator inhibitor-1 is a major stress-regulated gene: implications for stress-induced thrombosis in aged individuals. Proc Natl Acad Sci U S A 2002; 99 (2) 890-895
  CrossrefPubMedGoogle Scholar
• 18 Takeshita K, Hayashi M, Iino S , et al. Increased expression of plasminogen activator inhibitor-1 in cardiomyocytes contributes to cardiac fibrosis after myocardial infarction. Am J Pathol 2004; 164 (2) 449-456
  CrossrefPubMedGoogle Scholar
• 19 Naito M, Funaki C, Hayashi T , et al. Substrate-bound fibrinogen, fibrin and other cell attachment-promoting proteins as a scaffold for cultured vascular smooth muscle cells. Atherosclerosis 1992; 96 (2-3) 227-234
  CrossrefPubMedGoogle Scholar
• 20 Smith EB, Cochran S. Factors influencing the accumulation in fibrous plaques of lipid derived from low density lipoprotein. II. Preferential immobilization of lipoprotein (a) (Lp(a)). Atherosclerosis 1990; 84 (2-3) 173-181
  CrossrefPubMedGoogle Scholar
• 21 Eitzman DT, Westrick RJ, Xu Z, Tyson J, Ginsburg D. Plasminogen activator inhibitor-1 deficiency protects against atherosclerosis progression in the mouse carotid artery. Blood 2000; 96 (13) 4212-4215
  PubMedGoogle Scholar
• 22 Arenillas JF, Alvarez-Sabín J, Molina CA , et al. Progression of symptomatic intracranial large artery atherosclerosis is associated with a proinflammatory state and impaired fibrinolysis. Stroke 2008; 39 (5) 1456-1463
  CrossrefPubMedGoogle Scholar
• 23 Juhan-Vague I, Alessi MC, Vague P. Increased plasma plasminogen activator inhibitor 1 levels. A possible link between insulin resistance and atherothrombosis. Diabetologia 1991; 34 (7) 457-462
  CrossrefPubMedGoogle Scholar
• 24 Schneiderman J, Sawdey MS, Keeton MR , et al. Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries. Proc Natl Acad Sci U S A 1992; 89 (15) 6998-7002
  CrossrefPubMedGoogle Scholar
• 25 Chomiki N, Henry M, Alessi MC, Anfosso F, Juhan-Vague I. Plasminogen activator inhibitor-1 expression in human liver and healthy or atherosclerotic vessel walls. Thromb Haemost 1994; 72 (1) 44-53
  PubMedGoogle Scholar
• 26 Cristofalo VJ, Pignolo RJ. Molecular markers of senescence in fibroblast-like cultures. Exp Gerontol 1996; 31 (1-2) 111-123
  CrossrefPubMedGoogle Scholar
• 27 Campisi J, d'Adda di Fagagna F. Cellular senescence: when bad things happen to good cells. Nat Rev Mol Cell Biol 2007; 8 (9) 729-740
  CrossrefPubMedGoogle Scholar
• 28 Rerolle JP, Hertig A, Nguyen G, Sraer JD, Rondeau EP. Plasminogen activator inhibitor type 1 is a potential target in renal fibrogenesis. Kidney Int 2000; 58 (5) 1841-1850
  CrossrefPubMedGoogle Scholar
• 29 Oikawa T, Freeman M, Lo W, Vaughan DE, Fogo A. Modulation of plasminogen activator inhibitor-1 in vivo: a new mechanism for the anti-fibrotic effect of renin-angiotensin inhibition. Kidney Int 1997; 51 (1) 164-172
  CrossrefPubMedGoogle Scholar
• 30 Yamamoto K, Loskutoff DJ. The kidneys of mice with autoimmune disease acquire a hypofibrinolytic/procoagulant state that correlates with the development of glomerulonephritis and tissue microthrombosis. Am J Pathol 1997; 151 (3) 725-734
  PubMedGoogle Scholar
• 31 Zaman AK, Fujii S, Sawa H , et al. Angiotensin-converting enzyme inhibition attenuates hypofibrinolysis and reduces cardiac perivascular fibrosis in genetically obese diabetic mice. Circulation 2001; 103 (25) 3123-3128
  CrossrefPubMedGoogle Scholar
• 32 Kaikita K, Fogo AB, Ma L, Schoenhard JA, Brown NJ, Vaughan DE. Plasminogen activator inhibitor-1 deficiency prevents hypertension and vascular fibrosis in response to long-term nitric oxide synthase inhibition. Circulation 2001; 104 (7) 839-844
  CrossrefPubMedGoogle Scholar
• 33 Blasi F, Vassalli JD, Danø K. Urokinase-type plasminogen activator: proenzyme, receptor, and inhibitors. J Cell Biol 1987; 104 (4) 801-804
  CrossrefPubMedGoogle Scholar
• 34 Olman MA, Mackman N, Gladson CL, Moser KM, Loskutoff DJ. Changes in procoagulant and fibrinolytic gene expression during bleomycin-induced lung injury in the mouse. J Clin Invest 1995; 96 (3) 1621-1630
  CrossrefPubMedGoogle Scholar
• 35 Eitzman DT, McCoy RD, Zheng X , et al. Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene. J Clin Invest 1996; 97 (1) 232-237
  CrossrefPubMedGoogle Scholar
• 36 Vaughan DE, Lazos SA, Tong K. Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. A potential link between the renin-angiotensin system and thrombosis. J Clin Invest 1995; 95 (3) 995-1001
  CrossrefPubMedGoogle Scholar
• 37 Koh KK, Ahn JY, Han SH , et al. Pleiotropic effects of angiotensin II receptor blocker in hypertensive patients. J Am Coll Cardiol 2003; 42 (5) 905-910
  CrossrefPubMedGoogle Scholar
• 38 Okada H, Watanabe Y, Kikuta T , et al. Bradykinin decreases plasminogen activator inhibitor-1 expression and facilitates matrix degradation in the renal tubulointerstitium under angiotensin-converting enzyme blockade. J Am Soc Nephrol 2004; 15 (9) 2404-2413
  CrossrefPubMedGoogle Scholar
• 39 Brown NJ, Agirbasli MA, Williams GH, Litchfield WR, Vaughan DE. Effect of activation and inhibition of the renin-angiotensin system on plasma PAI-1. Hypertension 1998; 32 (6) 965-971
  CrossrefPubMedGoogle Scholar
• 40 Matsushita H, Chang E, Glassford AJ, Cooke JP, Chiu CP, Tsao PS. eNOS activity is reduced in senescent human endothelial cells: Preservation by hTERT immortalization. Circ Res 2001; 89 (9) 793-798
  CrossrefPubMedGoogle Scholar
• 41 Hayashi T, Matsui-Hirai H, Miyazaki-Akita A , et al. Endothelial cellular senescence is inhibited by nitric oxide: implications in atherosclerosis associated with menopause and diabetes. Proc Natl Acad Sci U S A 2006; 103 (45) 17018-17023
  CrossrefPubMedGoogle Scholar
• 42 Bouchie JL, Hansen H, Feener EP. Natriuretic factors and nitric oxide suppress plasminogen activator inhibitor-1 expression in vascular smooth muscle cells. Role of cGMP in the regulation of the plasminogen system. Arterioscler Thromb Vasc Biol 1998; 18 (11) 1771-1779
  CrossrefPubMedGoogle Scholar
• 43 Katoh M, Egashira K, Mitsui T, Chishima S, Takeshita A, Narita H. Angiotensin-converting enzyme inhibitor prevents plasminogen activator inhibitor-1 expression in a rat model with cardiovascular remodeling induced by chronic inhibition of nitric oxide synthesis. J Mol Cell Cardiol 2000; 32 (1) 73-83
  CrossrefPubMedGoogle Scholar
• 44 Weisberg AD, Albornoz F, Griffin JP , et al. Pharmacological inhibition and genetic deficiency of plasminogen activator inhibitor-1 attenuates angiotensin II/salt-induced aortic remodeling. Arterioscler Thromb Vasc Biol 2005; 25 (2) 365-371
  PubMedGoogle Scholar
• 45 Boe AE, Eren M, Murphy SB , et al. Plasminogen activator inhibitor-1 antagonist TM5441 attenuates Nω-nitro-L-arginine methyl ester-induced hypertension and vascular senescence. Circulation 2013; 128 (21) 2318-2324
  CrossrefPubMedGoogle Scholar
• 46 Juhan-Vague I, Pyke SD, Alessi MC, Jespersen J, Haverkate F, Thompson SG. Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. ECAT Study Group. European Concerted Action on Thrombosis and Disabilities. Circulation 1996; 94 (9) 2057-2063
  CrossrefPubMedGoogle Scholar
• 47 Hamsten A, Wiman B, de Faire U, Blombäck M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 1985; 313 (25) 1557-1563
  CrossrefPubMedGoogle Scholar
• 48 Hamsten A, de Faire U, Walldius G , et al. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 1987; 2 (8549) 3-9
  PubMedGoogle Scholar
• 49 Collet JP, Montalescot G, Vicaut E , et al. Acute release of plasminogen activator inhibitor-1 in ST-segment elevation myocardial infarction predicts mortality. Circulation 2003; 108 (4) 391-394
  CrossrefPubMedGoogle Scholar
• 50 Iacoviello L, Agnoli C, De Curtis A , et al. Type 1 plasminogen activator inhibitor as a common risk factor for cancer and ischaemic vascular disease: the EPICOR study. BMJ Open 2013; 3 (11) e003725
  Google Scholar
• 51 Eriksson P, Kallin B, van 't Hooft FM, Båvenholm P, Hamsten A. Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci U S A 1995; 92 (6) 1851-1855
  CrossrefPubMedGoogle Scholar
• 52 Hultman K, Björklund U, Hansson E, Jern C. Potentiating effect of endothelial cells on astrocytic plasminogen activator inhibitor type-1 gene expression in an in vitro model of the blood-brain barrier. Neuroscience 2010; 166 (2) 408-415
  CrossrefPubMedGoogle Scholar
• 53 Nagai N, Suzuki Y, Van Hoef B, Lijnen HR, Collen D. Effects of plasminogen activator inhibitor-1 on ischemic brain injury in permanent and thrombotic middle cerebral artery occlusion models in mice. J Thromb Haemost 2005; 3 (7) 1379-1384
  CrossrefPubMedGoogle Scholar
• 54 Tjärnlund-Wolf A, Brogren H, Lo EH, Wang X. Plasminogen activator inhibitor-1 and thrombotic cerebrovascular diseases. Stroke 2012; 43 (10) 2833-2839
  CrossrefPubMedGoogle Scholar
• 55 Dohgu S, Takata F, Matsumoto J , et al. Autocrine and paracrine up-regulation of blood-brain barrier function by plasminogen activator inhibitor-1. Microvasc Res 2011; 81 (1) 103-107
  CrossrefPubMedGoogle Scholar
• 56 Soeda S, Koyanagi S, Kuramoto Y , et al. Anti-apoptotic roles of plasminogen activator inhibitor-1 as a neurotrophic factor in the central nervous system. Thromb Haemost 2008; 100 (6) 1014-1020
  PubMedGoogle Scholar
• 57 McGill JB, Schneider DJ, Arfken CL, Lucore CL, Sobel BE. Factors responsible for impaired fibrinolysis in obese subjects and NIDDM patients. Diabetes 1994; 43 (1) 104-109
  CrossrefPubMedGoogle Scholar
• 58 Vague P, Juhan-Vague I, Aillaud MF , et al. Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level, and relative body weight in normal and obese subjects. Metabolism 1986; 35 (3) 250-253
  CrossrefPubMedGoogle Scholar
• 59 Brouwers MC, Govers-Riemslag J, Schalkwijk CG , et al. Plasma PAI-1 levels are independently related to fatty liver and hypertriglyceridemia in familial combined hyperlipidemia, involvement of apolipoprotein E. Thromb Res 2008; 122 (4) 466-472
  CrossrefPubMedGoogle Scholar
• 60 Shimomura I, Funahashi T, Takahashi M , et al. Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity. Nat Med 1996; 2 (7) 800-803
  CrossrefPubMedGoogle Scholar
• 61 Festa A, D'Agostino Jr R, Tracy RP, Haffner SM ; Insulin Resistance Atherosclerosis Study. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes 2002; 51 (4) 1131-1137
  CrossrefPubMedGoogle Scholar
• 62 Samad F, Loskutoff DJ. Tissue distribution and regulation of plasminogen activator inhibitor-1 in obese mice. Mol Med 1996; 2 (5) 568-582
  PubMedGoogle Scholar
• 63 Ma LJ, Mao SL, Taylor KL , et al. Prevention of obesity and insulin resistance in mice lacking plasminogen activator inhibitor 1. Diabetes 2004; 53 (2) 336-346
  CrossrefPubMedGoogle Scholar
• 64 Gabriely I, Yang XM, Cases JA, Ma XH, Rossetti L, Barzilai N. Hyperglycemia induces PAI-1 gene expression in adipose tissue by activation of the hexosamine biosynthetic pathway. Atherosclerosis 2002; 160 (1) 115-122
  CrossrefPubMedGoogle Scholar
• 65 Samad F, Pandey M, Bell PA, Loskutoff DJ. Insulin continues to induce plasminogen activator inhibitor 1 gene expression in insulin-resistant mice and adipocytes. Mol Med 2000; 6 (8) 680-692
  PubMedGoogle Scholar
• 66 Sobel BE, Hardison RM, Genuth S , et al; BARI 2D Investigators. Profibrinolytic, antithrombotic, and antiinflammatory effects of an insulin-sensitizing strategy in patients in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. Circulation 2011; 124 (6) 695-703
  CrossrefPubMedGoogle Scholar
• 67 Nishimura S, Manabe I, Nagai R. Adipose tissue inflammation in obesity and metabolic syndrome. Discov Med 2009; 8 (41) 55-60
  PubMedGoogle Scholar
• 68 Uchida Y, Takeshita K, Yamamoto K , et al. Stress augments insulin resistance and prothrombotic state: role of visceral adipose-derived monocyte chemoattractant protein-1. Diabetes 2012; 61 (6) 1552-1561
  CrossrefPubMedGoogle Scholar
• 69 Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissue expression of tumor necrosis factor-α in human obesity and insulin resistance. J Clin Invest 1995; 95 (5) 2409-2415
  CrossrefPubMedGoogle Scholar
• 70 Samad F, Uysal KT, Wiesbrock SM, Pandey M, Hotamisligil GS, Loskutoff DJ. Tumor necrosis factor α is a key component in the obesity-linked elevation of plasminogen activator inhibitor 1. Proc Natl Acad Sci U S A 1999; 96 (12) 6902-6907
  CrossrefPubMedGoogle Scholar
• 71 Samad F, Yamamoto K, Pandey M, Loskutoff DJ. Elevated expression of transforming growth factor-β in adipose tissue from obese mice. Mol Med 1997; 3 (1) 37-48
  PubMedGoogle Scholar
• 72 Pralong G, Calandra T, Glauser M-P , et al. Plasminogen activator inhibitor 1: a new prognostic marker in septic shock. Thromb Haemost 1989; 61 (3) 459-462
  PubMedGoogle Scholar
• 73 Green J, Doughty L, Kaplan SS, Sasser H, Carcillo JA. The tissue factor and plasminogen activator inhibitor type-1 response in pediatric sepsis-induced multiple organ failure. Thromb Haemost 2002; 87 (2) 218-223
  PubMedGoogle Scholar
• 74 Emeis JJ, Brouwer A, Barelds RJ, Horan MA, Durham SK, Kooistra T. On the fibrinolytic system in aged rats, and its reactivity to endotoxin and cytokines. Thromb Haemost 1992; 67 (6) 697-701
  PubMedGoogle Scholar
• 75 Yamamoto K, Shimokawa T, Yi H , et al. Aging accelerates endotoxin-induced thrombosis : increased responses of plasminogen activator inhibitor-1 and lipopolysaccharide signaling with aging. Am J Pathol 2002; 161 (5) 1805-1814
  CrossrefPubMedGoogle Scholar
• 76 Rosas GO, Zieman SJ, Donabedian M, Vandegaer K, Hare JM. Augmented age-associated innate immune responses contribute to negative inotropic and lusitropic effects of lipopolysaccharide and interferon gamma. J Mol Cell Cardiol 2001; 33 (10) 1849-1859
  CrossrefPubMedGoogle Scholar
• 77 Newland JR, Haire WD. Elevated plasminogen activator inhibitor levels found in patients with malignant conditions. Am J Clin Pathol 1991; 96 (5) 602-604
  PubMedGoogle Scholar
• 78 Prendergast GC, Diamond LE, Dahl D, Cole MD. The c-myc-regulated gene mrl encodes plasminogen activator inhibitor 1. Mol Cell Biol 1990; 10 (3) 1265-1269
  PubMedGoogle Scholar
• 79 Boccaccio C, Sabatino G, Medico E , et al. The MET oncogene drives a genetic programme linking cancer to haemostasis. Nature 2005; 434 (7031) 396-400
  CrossrefPubMedGoogle Scholar
• 80 Kristensen P, Pyke C, Lund LR, Andreasen PA, Danø K. Plasminogen activator inhibitor-type 1 in Lewis lung carcinoma. Histochemistry 1990; 93 (6) 559-566
  CrossrefPubMedGoogle Scholar
• 81 Pyke C, Kristensen P, Ralfkiaer E, Eriksen J, Danø K. The plasminogen activation system in human colon cancer: messenger RNA for the inhibitor PAI-1 is located in endothelial cells in the tumor stroma. Cancer Res 1991; 51 (15) 4067-4071
  PubMedGoogle Scholar
• 82 Pedersen H, Brünner N, Francis D , et al. Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue. Cancer Res 1994; 54 (17) 4671-4675
  PubMedGoogle Scholar
• 83 Nekarda H, Schmitt M, Ulm K , et al. Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer. Cancer Res 1994; 54 (11) 2900-2907
  PubMedGoogle Scholar
• 84 Kuhn W, Schmalfeldt B, Reuning U , et al. Prognostic significance of urokinase (uPA) and its inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO IIIc. Br J Cancer 1999; 79 (11-12) 1746-1751
  CrossrefPubMedGoogle Scholar
• 85 Kobayashi H, Fujishiro S, Terao T. Impact of urokinase-type plasminogen activator and its inhibitor type 1 on prognosis in cervical cancer of the uterus. Cancer Res 1994; 54 (24) 6539-6548
  PubMedGoogle Scholar
• 86 Danø K, Andreasen PA, Grøndahl-Hansen J, Kristensen P, Nielsen LS, Skriver L. Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res 1985; 44: 139-266
  PubMedGoogle Scholar
• 87 Bajou K, Noël A, Gerard RD , et al. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat Med 1998; 4 (8) 923-928
  CrossrefPubMedGoogle Scholar
• 88 Bajou K, Masson V, Gerard RD , et al. The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin. Implications for antiangiogenic strategies. J Cell Biol 2001; 152 (4) 777-784
  CrossrefPubMedGoogle Scholar
• 89 Rosengren A, Hawken S, Ôunpuu S , et al; INTERHEART investigators. Association of psychosocial risk factors with risk of acute myocardial infarction in 11119 cases and 13648 controls from 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364 (9438) 953-962
  Google Scholar
• 90 Räikkönen K, Lassila R, Keltikangas-Järvinen L, Hautanen A. Association of chronic stress with plasminogen activator inhibitor-1 in healthy middle-aged men. Arterioscler Thromb Vasc Biol 1996; 16 (3) 363-367
  CrossrefPubMedGoogle Scholar
• 91 Supiano MA, Hogikyan RV, Sidani MA, Galecki AT, Krueger JL. Sympathetic nervous system activity and alpha-adrenergic responsiveness in older hypertensive humans. Am J Physiol 1999; 276 (3 Pt 1) E519-E528
  PubMedGoogle Scholar
• 92 Larsson PT, Wiman B, Olsson G, Angelin B, Hjemdahl P. Influence of metoprolol treatment on sympatho-adrenal activation of fibrinolysis. Thromb Haemost 1990; 63 (3) 482-487
  PubMedGoogle Scholar
• 93 Vulin AI, Stanley FM. Oxidative stress activates the plasminogen activator inhibitor type 1 (PAI-1) promoter through an AP-1 response element and cooperates with insulin for additive effects on PAI-1 transcription. J Biol Chem 2004; 279 (24) 25172-25178
  CrossrefPubMedGoogle Scholar
• 94 Konkle BA, Schuster SJ, Kelly MD , et al. Plasminogen activator inhibitor-1 messenger RNA expression is induced in rat hepatocytes in vivo by dexamethasone. Blood 1992; 79 (10) 2636-2642
  PubMedGoogle Scholar
• 95 Yamamoto K, Shimokawa T, Yi H , et al. Aging and obesity augment the stress-induced expression of tissue factor gene in the mouse. Blood 2002; 100 (12) 4011-4018
  CrossrefPubMedGoogle Scholar
• 96 Takeshita K, Yamamoto K, Ito M , et al. Increased expression of plasminogen activator inhibitor-1 with fibrin deposition in a murine model of aging, “Klotho” mouse. Semin Thromb Hemost 2002; 28 (6) 545-554
  Article in Thieme ConnectPubMedGoogle Scholar
• 97 Goldstein S, Moerman EJ, Fujii S, Sobel BE. Overexpression of plasminogen activator inhibitor type-1 in senescent fibroblasts from normal subjects and those with Werner syndrome. J Cell Physiol 1994; 161 (3) 571-579
  CrossrefPubMedGoogle Scholar
• 98 Mu XC, Higgins PJ. Differential growth state-dependent regulation of plasminogen activator inhibitor type-1 expression in senescent IMR-90 human diploid fibroblasts. J Cell Physiol 1995; 165 (3) 647-657
  CrossrefPubMedGoogle Scholar
• 99 Kunz C, Pebler S, Otte J, von der Ahe D. Differential regulation of plasminogen activator and inhibitor gene transcription by the tumor suppressor p53. Nucleic Acids Res 1995; 23 (18) 3710-3717
  CrossrefPubMedGoogle Scholar
• 100 Kortlever RM, Higgins PJ, Bernards R. Plasminogen activator inhibitor-1 is a critical downstream target of p53 in the induction of replicative senescence. Nat Cell Biol 2006; 8 (8) 877-884
  PubMedGoogle Scholar